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4ABSTRACT
Rational & Objective: Data on outcomes of patients with end-stage renal disease (ESRD)
secondary to systemic sclerosis (scleroderma) requiring renal replacement therapy (RRT) is
limited. We examined the incidence, prevalence and outcomes of European patients starting
RRT for ESRD due to scleroderma.
Study Design: Cohort study.
Setting & Participants: Nineteen renal registries providing data to the ERA-EDTA Registry
between 2002-2013.
Predictor: Patients with scleroderma versus two age- and sex-matched control groups
without scleroderma (diabetes mellitus and disease other than diabetes).
Outcomes: Incidence, prevalence and survival.
Analytic approach: Incidence and prevalence was standardised to the European Union of
2005. Survival analyses were performed using Kaplan Meier and Cox regression.
Results: 342 patients with scleroderma (0.14% incident RRT patients) were included. The
adjusted annual incidence of RRT for ESRD due to scleroderma varied between 0.11-0.26 per
million population and the adjusted prevalence between 0.73-0.95. Recovery of independent
renal function was greatest in the scleroderma group (7.6% vs. 0.6% in diabetes and 2.1% in
non-diabetes, both P<0.001), though time required to achieve recovery was longer. In patients
with scleroderma, 5-year survival probability from day 91 of RRT was 38.9% (95%
confidence interval (CI):32.0%-45.8%), 5-year post-transplant patient survival was 88.2%
(95%CI:75.3%-94.6%) and 5-year allograft survival was 72.4% (95%CI:55.0%-84.0%). The
adjusted mortality from day 91 on RRT was higher in patients with scleroderma than in both
control groups (hazard ratio: 1.25, 95%CI:1.05-1.48, and 2.00 95%CI=1.69-2.39). In contrast,
patient and graft survival after kidney transplantation did not differ between patients with
scleroderma and other groups.
5Limitations: No data on extra-renal manifestations, treatment or recurrence.
Conclusions: Survival in patients with scleroderma on RRT was worse than in other causes
of ESRD. Patient survival after transplantation was similar to the control groups. In this study,
patients with scleroderma had higher renal function recovery rates than controls.
Index words: incidence, dialysis, end-stage renal disease, outcomes, scleroderma, kidney
transplantation
Summary: Scleroderma is a rare chronic connective tissue disease with multi-organ
involvement. There is limited published data on the outcomes of patients with end-stage renal
disease (ESRD) secondary to scleroderma requiring renal replacement therapy (RRT); i.e.
dialysis or kidney transplantation. In this European matched-cohort study we examined the
incidence, prevalence and outcomes of 342 patients receiving RRT for ESRD due to
scleroderma between 2002-2013. The matched controls had a diagnosis of diabetes mellitus
or all other diagnoses except diabetes mellitus or scleroderma. Patients with scleroderma
receiving RRT had a higher rate of kidney function recovery than the matched controls,
though their overall survival was worse. Transplanted patients with scleroderma showed
similar survival to the matched-controls, supporting the practice of kidney transplantation in
these patients. However, given that these patients had a relatively high rate of recovery of
their kidney function after starting dialysis we recommend a period of observation before
kidney transplantation is performed.
6INTRODUCTION
Systemic sclerosis (also referred to as scleroderma) is a rare chronic connective tissue disease
with multi-organ involvement characterized by immune activation, vasculopathy, fibroblast
dysfunction and excessive collagen accumulation in the skin and internal organs [1-3].
Renal disease in patients with scleroderma, particularly scleroderma renal crisis, result in
significant morbidity and mortality [1]. Scleroderma renal crisis typically manifests with an
acute onset of accelerated hypertension, rapidly progressive renal failure, frequently
accompanied by microangiopathic haemolytic anaemia and thrombocytopenia. Occurring in
approximately 3-10% of the scleroderma population, severe renal disease is commonly seen
in patients with diffuse rather than limited cutaneous scleroderma [1, 4]. Until the 1970s,
scleroderma renal crisis was recognized as the main cause of death in patients with
scleroderma, though since the introduction of treatment with ACE inhibitors and reduction of
corticosteroid doses the prognosis has substantially improved [4]. Nevertheless, about 25-50%
of patients with scleroderma renal crisis will develop end-stage renal disease (ESRD) and the
mortality associated with this condition remains high [1, 3-7].
There is limited knowledge regarding the prevalence of scleroderma renal crisis requiring
renal replacement therapy (RRT) [8] and due to the infrequency of this condition there are a
limited number of large multicentre or registry-based studies available [3-7, 9-11]. While the
outcome of patients with scleroderma on dialysis seems to be uniformly worse than that of
patients with other causes of ESRD [7, 11], the outcomes of kidney transplantation are less
clear. It is known that renal function may recover after commencing RRT and there is an
ongoing discussion regarding the optimal timing of kidney transplantation in patients with
scleroderma [5, 12, 13].
We analysed the trends in incidence and prevalence of RRT for ESRD due to scleroderma in
the European Renal Association - European Dialysis and Transplant Association (ERA-
7EDTA) Registry and determined the patient characteristics, patient survival on RRT, patient
and graft survival after kidney transplantation and causes of death in a large cohort of
European patients initiating RRT between 2002 and 2013.
METHODS
Patients and data collection
The ERA-EDTA Registry collects data annually on patients starting RRT from national and
regional renal registries in Europe. Renal registries sending individual patient level data to the
ERA-EDTA Registry between 2002 and 2013, with at least 50% percent coverage of the
general population were included in the study. The renal registries included were Austria,
Dutch-speaking Belgium, French-speaking Belgium, Denmark, Finland, Greece, Iceland, the
Netherlands, Norway, the Spanish regional renal registries of Andalusia, Aragon, Asturias,
Basque Country, Cantabria, Castile and León, Catalonia, and Valencia, Sweden, United
Kingdom: England, Northern Ireland and Wales, and United Kingdom: Scotland. The details
of methods of data collection and data processing are described elsewhere [14]. The cause of
death was defined and categorized according to the ERA-EDTA coding system [14]. All
national and regional registries contributing data to the ERA-EDTA Registry followed
national legislation with regard to ethics committee approval. Additional informed patient
consent was not required for this study due to the de-identified nature of the information
obtained.
Cases and matched control groups
The incidence, prevalence and patient survival on RRT analyses refer to patients starting RRT
for ESRD due to “systemic sclerosis (scleroderma)” (ERA-EDTA primary renal disease
[PRD] code 87 [14]), as recorded by the responsible physician. Patient and graft survival after
8kidney transplantation refer to all patients with a diagnosis of scleroderma, or the matched
controls (described below) who received their first kidney-only transplant between 1st January
2002 and 31st December 2013. This included patients who commenced RRT for ESRD before
2002. Age and sex were compared between scleroderma and non-scleroderma patients. We
then formed two matched control groups of patients without scleroderma: 1) diabetes mellitus
(PRD codes 80 and 81); and 2) patients without scleroderma and without diabetes mellitus
(“non-diabetes”). Due to the low number of scleroderma patients, we matched 10 controls to 1
case. We matched on age group at the start of RRT (5-year age groups) and sex, when
comparing patients receiving RRT. When comparing transplant recipients we matched on age
group at the time of kidney transplantation (5-year age groups) and sex.
Statistical analysis
Time trends in the incidence of RRT per million population (pmp) were studied by year
according to the date of RRT onset for all participating European countries/regions combined.
Incidence was then assessed by country/region for the whole study period. Time trends in the
prevalence of RRT pmp by year, defined as the number of patients alive and receiving RRT
on 31st December of that year, divided by the mid-year general population, were studied for
all participating European countries/regions. Incidence and prevalence rates were adjusted for
age and sex using the European Standard Population of 2005 as a reference [15]. The time
trends for the incidence rates and prevalence were estimated using Poisson regression, with
the observed rate as the outcome and the year as the explanatory variable. The mean
percentage annual change (MPAC) and its 95% confidence interval were computed from each
model as [exp(β)−1] × 100, where β denotes the regression coefficient of time (i.e., change in
the event rate per year). To examine whether the trends were linear, we performed Joinpoint
regression analysis. Joinpoint regression allows the identification of points in time where a
9significant change in the linear slope of a trend occurs. The analysis starts with zero joinpoints
(i.e. a straight line) and then tests whether one or more joinpoints are significantly different
and must be added to the model [16]. This was performed using the Joinpoint software
(version 4.0.4) [17].
To compare the characteristics of scleroderma patients receiving RRT with each of the
matched control groups separately, the Wilcoxon test was used for continuous variables with
a skewed distribution, and the McNemar square test for categorical variables. A two-tailed p-
value <0.05 was considered as statistically significant. The first treatment modality was
defined as treatment at day 91 after the start of RRT, as some patients received haemodialysis
(HD) for a short period, while preparations were made for peritoneal dialysis (PD).
The Kaplan-Meier method and Cox regression analysis were used for the survival analyses.
The patient survival on RRT was examined for individuals who initiated RRT for ESRD due
to scleroderma between 2002 and 2013, and was compared with each of the matched control
groups separately. Day 91 after the onset of RRT was taken as the starting point for these
survival analyses. The death of the patient was the event studied. Follow-up time was
censored at recovery of renal function, loss to follow-up and the end of the follow-up period
(31st December 2013). Within the Cox regression analysis we took the strata (matched
groups) into account. Patient  survival on RRT was adjusted for time period (with three
intervals, 2002-2005, 2006-2009 and 2010-2013) and country. Patient and graft survival after
kidney transplantation was examined for patients who received their first transplant between
2002 and 2013 (regardless of the RRT start date). The scleroderma group was compared with
each of the matched control groups separately. In these analyses the date of the first kidney
transplant was defined as the first day of follow-up. For patient survival after transplantation,
the event studied was death, and in case of graft survival, the events were graft failure and
death. Reasons for censoring were loss to follow-up and the end of follow-up period (31st
10
December 2013). In the Cox regression analysis, patient and graft survival were adjusted for
time period (as described above), country and donor type.
All analyses were performed using SAS 9.3.
RESULTS
Incidence and prevalence
A total of 342 patients with scleroderma were identified; comprising 0.14% of 236,082
patients starting RRT between 2002 and 2013.
The adjusted incidence of RRT for ESRD due to scleroderma between 2002 and 2013 was
0.18 pmp, ranging from 0.0 to 0.25 pmp between regions/countries (Table 1). The adjusted
incidence of RRT for ESRD due to scleroderma was 0.26 pmp in 2002 and 0.12 pmp in 2013
(Table 2). There was a trend towards a decline in the incidence pmp over time but this did not
reach statistical significance (MPAC = -3.6; [95%CI: -7.9; 0.8]).
During the study period, the adjusted prevalence of RRT for ESRD due to scleroderma varied
between 0.73 and 0.95 pmp per year (Table 2) with a statistically significant increase in the
prevalence pmp (MPAC = 2.0; [95%CI: 1.0; 2.9]).
Patient characteristics
Patients commencing RRT for ESRD due to scleroderma were significantly younger than
patients (before matching) with other diagnoses (median age [25th-75th percentile] 59.9 [50.2-
68.2] years for patients with scleroderma vs. 67.2 [54.4-76.1] years for all non-scleroderma
patients; P<0.001). The proportion of women within the scleroderma group was higher than
that of non-scleroderma group (68.1% vs. 38.2%; P<0.001).
Baseline characteristics are displayed in Table 3 for patients initiating RRT for ESRD due to
scleroderma and for the control groups, matched on age group and sex. The treatment
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modality at day 91 after the start of RRT was different in patients with scleroderma compared
with the matched control groups, with a higher percentage of HD in the scleroderma patients
(Table 3; P≤0.01 for both comparisons).
A higher number of deaths during the first 90 days on RRT was observed in the scleroderma
patients compared with both matched control groups (12.6% vs. 3.9% and 4.0%, respectively,
Table 3; P<0.001 for both comparisons).
The percentage of patients who achieved dialysis independency during the first 90 days on
RRT did not differ between the scleroderma patients and the matched control groups.
However, a higher proportion of patients with scleroderma recovered renal function beyond
this time period (7.6% vs. 0.7% and 2.0% in the matched control groups diabetes and non-
diabetes, respectively; both P<0.001). In patients who recovered renal function, the time to
recovery was longer in those with a diagnosis of scleroderma than in both matched control
groups (median 255.5 days [25th-75th percentile]: 130-454] vs. 112.0 [40.5-178] days
(diabetes) and 167.5 [60-353] days (non-diabetes); both P<0.05) . The vast majority of
patients who recovered renal function were female; 80.8% in patients with scleroderma,
83.2% for the matched control group with diabetes mellitus (p<0.05) and 60.0% in the non-
diabetics matched control group (p<0.001). Median age was significantly lower in patients
with scleroderma who recovered renal function than in both matched control groups (median
52.1 [25th-75th percentile: 47.9-56.8] vs. 64.6 [54.8-71.7] (diabetes) and 60.6 [50.4-66.3] (non-
diabetes) (p<0.05).  A total of 46 of the 342 (13.7%) scleroderma patients who started RRT
between 2002 and 2013 received a kidney transplant during the study period. This percentage
was 18.7% for the control group diabetes mellitus and 27.1% for the control group non-
diabetes mellitus (both p<0.001 in comparison with scleroderma patients).
Patient survival on RRT
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Figure 1a depicts the 5-year patient survival on RRT after day 91 for patients who started
RRT for ESRD due to scleroderma (38.9% [95%CI: 32.0% - 45.8%]) and for the matched
control groups diabetes mellitus (46.0% [95%CI: 43.9% - 48.0%]), and non-diabetes mellitus
(63.6% [95% CI: 61.6% - 65.6%]).
After adjustment for time period and country, the mortality from day 91 after the
commencement of RRT was higher in patients with scleroderma than in both matched control
groups (i.e. diabetes and non-diabetes, HR= 1.25 [95%CI: 1.05 – 1.48] and 2.00 [95%CI:
1.69-2.39], respectively; Figure 2a).
Patient and graft survival after kidney transplantation
Of the 57 patients with scleroderma who received their first kidney transplant between 2002
and 2013, the percentage of patients with a living donor transplant was 35.6% in the
scleroderma group, and 17.8% and 29.8% in the matched control groups of diabetes and non-
diabetes, respectively.
The median time on dialysis before receiving their first transplant was significantly greater in
the patients with scleroderma (2.9 years [25th-75th percentile:1.6-4.7]) compared with the
matched control groups (diabetes: 1.6 years [0.8-2.9]; and non-diabetes: 1.6 years [0.5-3.6],
both p<0.001).
Figure 1b and 1c present the 5-year patient and graft survival after receiving a first kidney
transplant, respectively, for patients with scleroderma (88.2% [95%CI: 75.3% - 94.6%] and
72.4% [95%CI: 55.0% - 84.0%]) and for the matched control groups with diabetes mellitus
(84.3% [95%CI: 80.5% - 87.4%] and 76.5% [95%CI: 72.2% - 80.3%]) and non-diabetes
patients (89.3% [95%CI: 86.0% - 91.8%] and 81.5% [95%CI: 77.6% - 84.8%]), matched on
age group at kidney transplantation and sex.
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The risk of death for patients with scleroderma after kidney transplantation, adjusted for
country, time period and donor type, did not differ from patients with diabetes or non-diabetes
(Figure 2b). Similarly, graft survival adjusted for country, time period and donor type did not
differ between the patients with scleroderma and the matched control groups (Figure 2c).
Causes of death
Table 4 shows the causes of death for patients who started RRT for ESRD due to scleroderma
and for the matched control groups since day 91. Patients with scleroderma had fewer deaths
due to cardiovascular events (particularly myocardial ischemia and cardiac arrest) compared
with the matched control group of patients with diabetes. Compared with the matched control
group of patients with non-diabetes, there were fewer deaths due to malignancy and cardiac
arrest among the patients with scleroderma. Conversely, there were more deaths due to heart
failure. A large proportion of deaths in the patients with scleroderma were reported as
“miscellaneous” or unknown.
DISCUSSION
Systemic sclerosis is a very rare cause of ESRD, and as such analysis of this condition
requires multi-centre, multi-national studies performed over a long period of time. This study
describes the characteristics and outcomes of patients with scleroderma requiring RRT in a
large European cohort. We found that the age and sex adjusted incidence of RRT for ESRD
due to scleroderma between 2002 and 2013 was only 0.18 pmp. There was a trend towards a
decline in the incidence over time but this did not reach statistical significance. Conversely
the prevalence significantly increased over the time period from 0.80 pmp in 2002 to 0.89
pmp in 2013. Furthermore, we observed that survival on RRT in patients with scleroderma
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was worse than in other causes of ESRD, whilst transplant recipients with scleroderma
showed a similar survival to the control groups.
Scleroderma is a rare disease with an estimated annual incidence of 10-20 pmp and a
prevalence of about 30-300 pmp. The occurrence of scleroderma is presumed to be higher in
North America or Australia than in Europe or Asia, even though epidemiological studies are
difficult to perform due to the low incidence and heterogeneity of the disease [18, 19]. The
overall prevalence of scleroderma in the general population has been reported to increase,
probably due to a greater awareness of the disease and improved patient survival [20],
whereas there is in more recent studies some evidence suggesting a lower incidence of
scleroderma renal crisis [1]. In keeping with this observation, we observed a non-statistically
significant trend towards a decline in the incidence of RRT for ESRD due to scleroderma over
time. However, as frequently seen in rare diseases with low numbers of patients, the number
of cases in each year fluctuated. In Australia and New Zealand the incidence of patients with
scleroderma requiring RRT for ESRD declined significantly between 2002 and 2013, from
0.51 pmp to 0.18 pmp [21]. The prevalence of RRT for ESRD caused by scleroderma
increased during the study period. This is most likely explained by the improved survival of
patients with scleroderma receiving RRT.
In this study, patients with scleroderma were less likely to be treated with PD than
haemodialysis when compared with the matched control groups. This is in contrast to the data
from the Australian and New Zealand registry where the use of PD was more common in
patients with scleroderma than in patients with other causes of ESRD. However, PD is also a
more frequent treatment option for ESRD in Australia than in Europe [11]. The choice of the
“optimal” modality of RRT in patients with scleroderma is generally considered problematic
[22].
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Scleroderma has long been recognized as a condition with a relatively high probability of
renal recovery, even in patients requiring long-term dialysis [23]. This has important
implications regarding the timing of kidney transplantation and some authors have
recommended treating patients initially with dialysis for up to two years [13], whereas, for
instance, the Canadian guidelines suggest that kidney transplantation could be considered in
patients with scleroderma who have had quiescent disease for at least six months off cytotoxic
agents and have limited extra-renal disease [12]. Previous reports have described renal
recovery in patients with scleroderma to be as high as 38% [1, 6]. However the Australian and
New Zealand Registry, which includes patients with presumed ESRD [11], reported renal
recovery at 10%, which is similar to the 7.6% observed in our study. The proportion of
patients with presumed ESRD who recovered renal function in this study was higher in
patients with ESRD secondary to scleroderma than in patients with other causes of ESRD. It
has been previously noted that systemic autoimmune diseases commonly show higher
recovery rates than other PRDs [24, 25]. Importantly, 25% of patients who recovered renal
function in the current study discontinued dialysis after more than 15 months of RRT,
supporting the recommendation of delaying kidney transplantation in these patients. This may
explain why the time spent on dialysis before transplantation was longer in patients with
scleroderma than in the matched control groups in our study.
In previous studies exploring the survival of patients with scleroderma receiving RRT, a
diagnosis of scleroderma mostly showed unfavourable outcomes [7, 11, 25] and was even
identified as an independent predictor of death (HR of 2.47) [11]. Similarly, in the present
study, we confirmed that both early and long-term mortality of patients with scleroderma
receiving RRT remains high, and that the prognosis is worse than that of RRT patients with
diabetes. Among the causes of death, cardiovascular events, especially ischemic heart disease,
were much less common in patients with scleroderma than in patients with diabetes.
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Nevertheless, detailed evaluation of the causes of death was limited due to the high number of
unknown or miscellaneous causes reported in the patients with scleroderma.
Interestingly, patient and graft survival after kidney transplantation did not differ between
patients with scleroderma and other PRDs. Given the poorer survival outcomes in patients
with scleroderma, but similar post-transplant survival outcomes one must consider it likely
that bias towards transplanting patients with scleroderma without major comorbidities i.e. the
healthiest patients exists. Furthermore given the small samples size one cannot rule out  a
possible type 2 error. Nevertheless, our findings support the use of kidney transplantation in at
least some patients with scleroderma, preferably those without major extra-renal
complications, although transplantation should be delayed due to the aforementioned chance
of renal recovery. The 5-year graft survival rate of 72.4% in our study is greater than the 3-
year graft survival of 60.3% in the study by Gibney et al. [9], or the 5-year graft survival of
56.7% in the study by Pham et al. [26], both using United States (US) data. Although direct
comparison is hardly possible, it may suggest improving survival over time, even though
there are known geographical differences, with a somewhat better graft survival in Europe
than in the US [27].
We are aware of the potential limitations of this study that include the registry-based nature of
the data with a lack of detailed information regarding the disease course of individual
patients, for example, disease duration prior to RRT, renal biopsy results, extent of extra-renal
involvement, administered treatment, or disease recurrence after kidney transplantation. It is
known that ESRD in some patients with scleroderma is not necessarily caused solely by
scleroderma renal crisis, they may have for example normotensive renal crisis, penicillamine-
associated nephropathy, scleroderma-associated vasculopathy, a mixed disease and overlap
with for example, ANCA-associated vasculitis, in which case their renal survival and renal
outcomes may be different [1, 28]. However, we were not able to distinguish such mixed
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causes of ESRD. Furthermore, on occasion it may be difficult to differentiate between acute
cases of kidney failure requiring short-term (but prolonged) dialysis from true ESRD in
patients with a diagnosis of scleroderma. The view regarding such patients may differ
between registries, some of which may not enter patients who recovered renal function as
ESRD into the database, even though the time on dialysis exceeded three months which is
typically the cut-off point for entering a patient requiring long-term RRT into the ESRD
registry. On the other hand, the ERA-EDTA Registry provides a unique opportunity to
analyse a large cohort of European patients with scleroderma receiving RRT and also allows
for the direct comparison of patients with scleroderma with other causes of ESRD.
In conclusion, we show that the overall survival of patients with scleroderma receiving RRT
is worse than that of patients with ESRD due to diabetes or other PRDs. Although limited by
a relatively low number of patients, our results suggest that kidney transplantation may be a
sound therapeutic option in some patients with ESRD due to scleroderma, as graft and patient
survival rates in this study were comparable with other non-diabetic causes of ESRD.
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Table 1. Incidence of renal replacement therapy (RRT) for end-stage renal disease secondary to scleroderma, by country/region from 2002 to
2013
*Pmp=per million population.
†N pmp are adjusted for the age and sex distribution using the European Standard Population of 2005 as reference.
All RRT Scleroderma
Country N N % N
 pmp
N
pmp*†
  Austria 14650 12 0.08 0.12 0.12
  Belgium: Dutch-speaking 13968 16 0.11 0.22 0.20
  Belgium: French-speaking 9943 11 0.11 0.20 0.23
  Denmark 8431 17 0.20 0.26 0.25
  Finland 5775 8 0.14 0.13 0.11
  Greece 26181 31 0.12 0.23 0.21
  Iceland   295  0    0   0    0
  Netherlands 22131 37 0.17 0.19 0.19
  Norway 5923 5 0.08 0.09 0.08
  Spain: Andalusia 11817 11 0.09 0.11 0.12
  Spain: Aragon 2031 3 0.15 0.19 0.18
  Spain: Asturias 1772 2 0.11 0.15 0.14
  Spain: Basque Country 3052 5 0.16 0.20 0.17
  Spain: Cantabria  833 0   0    0    0
  Spain: Castile and León 3654 8 0.22 0.27 0.23
  Spain: Catalonia 12298 20 0.16 0.23 0.24
  Spain: Valencian region 8582 7 0.08 0.12 0.12
  Sweden 13640 19 0.14 0.17 0.17
  United Kingdom 71106 130 0.18 0.19 0.19
  All countries 236082 342 0.14 0.18 0.18
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Table 2. Incidence and prevalence of renal replacement therapy for end-stage renal disease secondary to scleroderma per million population by year
from 2002 to 2013, and the mean percentage annual change (MPAC) with 95% confidence interval (95%CI) for all countries/regions combined,
adjusted for age and sex using the European Standard Population of 2005 as a reference.
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 MPAC (95%CI)
Incidence 0.26 0.22 0.20 0.20 0.17 0.20 0.20 0.11 0.15 0.27 0.14 0.12 -3.6 (-7.9; 0.8)
Prevalence 0.80 0.75 0.73 0.81 0.81 0.90 0.89 0.88 0.85 0.95 0.95 0.89 2.0 (1.0; 2.9)
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Table 3. Characteristics and treatment modality at day 91 after the onset of renal replacement therapy (RRT) in patients with end-stage renal
disease secondary to scleroderma and control groups matched on age group and sex*
Scleroderma Control group
DM#
Control group
Non-DM
Patients at day 1 of RRT, N 342 3420 3420
Female at day 1 of RRT, % 68.1 68.1 68.1
Median age at day 1 of RRT, years [25th-
75th percentile]
59.9
[50.2-68.2]
59.8
[50.3-68.1]
59.8
[50.3-68.2]
Patients in whom renal function recovered
within 90 days, N [%])
3 (0.9) 21 (0.6) 38 (1.1)
Patients who died within 90 days, N [%] 43 (12.6) 135 (3.9) 138 (4.0)
Loss to follow-up/missing data within 90
days, N [%])
0 (0) 7 (0.2) 15 (0.4)
Treatment discontinued/ limited care
within 90 days, N [%]
0 (0) 4 (0.1) 5 (0.2)
Patients at day 91 after start of RRT,
N [% of number of patients at day 1]
296 (86.5) 3253 (95.1) 3224 (94.3)
Female at day 91 of RRT, % 67.2 67.9 68.4
Median age at day 91 of RRT, years [25th-
75th percentile]
58.6
[49.4-68.1]
59.9
[50.2-68.2]
59.6
[49.9-68.1]
Treatment modality at day 91
  Haemodialysis, % 83.4 75.9 70.4
  Peritoneal dialysis, % 14.9 20.6 22.5
  Transplantation, % 1.7 3.5 7.1
* Control groups were matched on 5-year age groups and sex at day 1 after the initiation of RRT.
# DM = diabetes mellitus as primary renal disease; the matched control groups did not include patients with scleroderma.
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Table 4. Causes of death in patients starting renal replacement therapy (RRT) for end-stage renal disease secondary to scleroderma and the matched
control groups since day 91
Scleroderma
n=296
Control group*
DM
n=3,253
Control group*
Non-DM
n= 3,224
Number of deaths (%) 156 (52.7) 1,613 (49.6) 1,134 (35.2)
Cause of death % % P value# % P value#
Cardiovascular disease 21.2 36.3 <0.001 23.8 0.5
  Myocardial ischaemia/infarction 4.5 12.8 0.002 5.5 0.6
  Heart failure 8.3 5.3 0.1 4.4 0.03
  Cardiac arrest; other cause/unknown 3.9 12.0 0.002 9.1 0.03
  Cerebrovascular accident 4.5 6.2 0.4 4.9 0.8
Infection 14.1 17.3 0.3 15.4 0.7
Suicide/refusal of dialysis 3.9 1.7 0.06 2.6 0.4
Withdrawal from dialysis 5.8 5.8 0.9 5.6 0.9
Cachexia 3.9 1.6 0.04 2.0 0.2
Malignancy 1.9 3.8 0.2 10.4 <0.001
Miscellaneous 19.2 12.7 0.02 16.3 0.4
Unknown/unavailable/missing 30.1 20.8 0.007 23.9 0.09
Percentages may not add up to 100% because of rounding off. DM = diabetes mellitus as primary renal disease.
*Control groups are matched on 5-year age groups and sex; # comparison of control group with patients with scleroderma. The matched control
groups did not include patients with scleroderma.
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Legends to Figures
Figure 1
a. Kaplan-Meier survival analyses of patient survival on renal replacement therapy (RRT) for end-stage renal disease secondary to scleroderma
(n=296) from day 91, and for the matched control groups with diabetes mellitus (DM; n=3253) and without diabetes mellitus (non-DM; n=3224)
as primary renal disease. Control groups are matched on 5-year age groups at the onset of RRT and sex. Median age was 59.9 years and 68.1% were
female in the scleroderma group and in each matched control group. The matched control groups did not include patients with scleroderma.
b. Kaplan-Meier survival analyses of patient survival after kidney transplantation for end-stage renal disease secondary to scleroderma (n=57),
and for the matched control groups with diabetes mellitus (DM) and without diabetes mellitus (non-DM) as primary renal disease (n=565 for each
matched control group). Control groups are matched on 5-year age groups at the time of transplantation and sex. Median age was 49 years and 62.7%
were female in the scleroderma group and in each matched control group. The matched control groups did not include patients with scleroderma.
c. Kaplan-Meier survival analyses of graft survival after kidney transplantation for end-stage renal disease secondary to scleroderma (n=57), and
for the matched control groups with diabetes mellitus (DM) and without diabetes mellitus (non-DM) as primary renal disease (n=565 for each
matched control group). Control groups are matched on 5-year age groups at the time of transplantation and sex. Median age was 49 years and 62.7%
were female in the scleroderma group and in each matched control group. The matched control groups did not include patients with scleroderma.
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Figure 2.
a. Hazard ratios (HR; 95% confidence intervals) for death on RRT from day 91 for patients with scleroderma versus the matched control groups,
unadjusted and adjusted for time period and country. Control groups with diabetes mellitus (DM) and without diabetes mellitus (non-DM) as primary
renal disease are matched on 5-year age groups at the onset of renal replacement therapy and sex. The scleroderma group and each matched control
group had a median age of 59.9 years and 68.1% were female. The matched control groups did not include patients with scleroderma.
b. Hazard ratios (HR; 95% confidence intervals) for death after kidney transplantation for patients with scleroderma versus the matched control groups,
unadjusted and adjusted for time period, country and donor type. Control groups with diabetes mellitus (DM) and without diabetes mellitus (non-DM)
as primary renal disease are matched on 5-year age groups at the time of transplantation and sex. The scleroderma group and each matched control
group had a median age of 49 years and 62.7% were female. The matched control groups did not include patients with scleroderma.
c. Hazard ratios (HR; 95% confidence intervals) for graft failure after kidney transplantation in patients with scleroderma versus the matched control
groups, unadjusted and adjusted for time period, country and donor type. Control groups with diabetes mellitus (DM) and without diabetes mellitus
(non-DM) as primary renal disease are matched on 5-year age groups at the time of transplantation and sex. The scleroderma group and each matched
control group had a median age of 49 years and 62.7% were female. The matched control groups did not include patients with scleroderma.
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